Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma

Table 1 Clinical trials with reported results for rapamycin in post-liver transplantation hepatocellular carcinoma

Ref.	Patients (N)	Treatment	1-yr OS (%)	3-yr OS (%)	5-yr OS (%)	HCC recurrence HR (95%CI)
Grigg et al[11], 2019	968	RAPA vs CNI	NA	NA	67.6 vs 59.7	NA
Zhou et al[13], 2018	36	RAPA vs RAPA free	100 vs 77.8	94.5 vs 0	77.8 vs 0	NA
Toso et al[40], 2010	2491	RAPA vs RAPA free	NA	85.6 vs 79.2	83.1 vs 68.7	NA
Ling et al[41], 2020	204	RAPA vs RAPA free	97.4 vs 82.0	85.5 vs 71.9	NA	NA
Menon et al[42], 2013	474	RAPA vs CNI	94-95 vs 79-83	85 vs 66	80 vs 59-62	NA
Liang et al[43], 2012	2815	RAPA vs RAPA free	NA	NA	81.5 vs 68.1	NA
Yanik et al[44], 2016	3936	RAPA vs RAPA free	NA	NA	75.0 vs 75.0	0.86 vs 0.83
Geissler et al[47], 2016	525	RAPA vs RAPA free	96.0 vs 91.4	86.1 vs 78.5	79.4 vs 70.3	NA
Schnitzbauer et al[48], 2020	508	RAPA > 3 mo vs RAPA ≤ 3 mo	100 vs 89.9	87.7 vs 76.3	80.1 vs 67.0	NA
Xu et al[49], 2016	142	RAPA vs RAPA free	81.1 vs 85.3	60.3 vs 71.2	40.7 vs 43.5	NA
Na et al[61], 2016	39	RAPA + SOR vs RAPA + SOR free	NA	NA	NA	NA
Yang et al[65], 2020	64	RAPA vs TAC	54.5 vs 29.0	NA	NA	NA

OS: Overall survival; HR: Hazard ratio; CI: Confidence interval; RAPA: Rapamycin; CNI: Calcineurin inhibitor; NA: Not applicable; SOR: Sorafenib; TAC: Tacrolimus; LT: Liver transplantation.